Showing results (21-30 of 49) with videos related to
Sort By:
Pageof 5
Developmental Medicine and Child Neurology|May 24, 2021
Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measureHeather E Olson, Julia G Costantini, Lindsay C Swanson, et al.Contemporary Clinical Trials|February 12, 2022
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndromeJeffrey L Neul, Alan K Percy, Timothy A Benke, et al.Nature Medicine|October 18, 2005
NKCC1 transporter facilitates seizures in the developing brainVolodymyr I Dzhala, Delia M Talos, Dan A Sdrulla, et al.Journal of Autism and Developmental Disorders|March 4, 2024
Psychometric Assessment of the Rett Syndrome Caregiver Assessment of Symptom Severity (RCASS)Melissa Raspa, Angela Gwaltney, Carla Bann, et al.Med (New York, N.Y.)|June 25, 2024
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC studyAlan K Percy, Jeffrey L Neul, Timothy A Benke, et al.Epilepsy & Behavior : E&B|April 13, 2021
Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohortÁngel Aledo-Serrano, Patricia Gómez-Iglesias, Rafael Toledano, et al.Nature Medicine|June 8, 2023
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 studyJeffrey L Neul, Alan K Percy, Timothy A Benke, et al.Pediatric Neurology|January 17, 2024
Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett SyndromeJeffrey L Neul, Alan K Percy, Timothy A Benke, et al.American Journal of Medical Genetics. Part A|June 14, 2025
Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 VariantsTalia Thompson, Dennis Gurfinkel, Lori Silveira, et al.Med (New York, N.Y.)|July 18, 2024
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 studyAlan K Percy, Jeffrey L Neul, Timothy A Benke, et al.Pageof 5